Hence, investigating the molecular mechanisms by which PaPE-1 regulates hypoxia-/ischemia-related processes may lead to the development of a novel posttreatment therapy that targets the membrane-associated non-GPER ERs and opens up new therapeutic perspectives for stroke and perinatal asphyxia. This evidence concerns the gene GPER1 and Stroke.